Genocea Biosciences Company Profile (NASDAQ:GNCA)

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

Genocea Biosciences, Inc. (NASDAQ:GNCA) announced its earnings results on Wednesday, August, 9th. The company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.08. View Genocea Biosciences' Earnings History.

4 brokers have issued 12 month price targets for Genocea Biosciences' shares. Their forecasts range from $12.00 to $40.00. On average, they anticipate Genocea Biosciences' stock price to reach $21.75 in the next year. View Analyst Ratings for Genocea Biosciences.

Here are some recent quotes from research analysts about Genocea Biosciences stock:

• 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (8/17/2017)
• 2. Needham & Company LLC analysts commented, "Genocea announced positive results from its Phase 2b trial of GEN-003 in Herpes Simplex Type 2 (HSV2) in early Jan 2017. Given financial constraints, however, mgmt now plans to seek a collaborator prior to initiation of Phase 3 development. We believe this creates meaningful uncertainty for GEN-003 development timelines as well as the stock. Mgmt previously announced a shift in strategic focus from infectious disease to immuno-oncology. However, initial candidate from latter program is not expected to reach clinical development until YE17. We are downgrading to HOLD based on uncertainty around GEN-003 and lack of near-term milestones w/ immuno-oncology program. ATLAS platform holds substantial value and we believe stock remains attractive for long-term investors w/ horizon beyond 2017." (2/17/2017)

Some companies that are related to Genocea Biosciences include Voyager Therapeutics (VYGR), Organovo Holdings (ONVO), Protagonist Therapeutics (PTGX), Arbutus Biopharma Corporation (ABUS), NewLink Genetics Corporation (NLNK), Merrimack Pharmaceuticals (MACK), Compugen (CGEN), OncoMed Pharmaceuticals (OMED), Chromadex Corp (CDXC), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), CTI BioPharma Corp. (CTIC), Novelion Therapeutics (NVLN), Matinas BioPharma Holdings (MTNB), BioLineRx (BLRX), Pluristem Therapeutics (PSTI), Tissue Regenix Group PLC (TRX) and Oramed Pharmaceuticals (ORMP).

Genocea Biosciences' management team includes the folowing people:

• Katrine S. Bosley, Chairman of the Board
• William D. Clark, President, Chief Executive Officer, Director
• Jonathan M. Poole, Chief Financial Officer
• John E. Bishop Ph.D., Executive Vice President - Pharmaceutical Sciences
• Jessica Baker Flechtner Ph.D., Chief Scientific Officer
• Seth V. Hetherington M.D., Chief Medical Officer
• Eric S. Hoffman Ph.D., Chief Business Officer
• Ronald Harold Wilfred Cooper, Director
• George Siber M.D., Director
• Kenneth M. Bate, Independent Director

Genocea Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Franklin Resources Inc. (10.51%), Northpointe Capital LLC (4.69%), Vanguard Group Inc. (3.01%), AXA (2.06%) and Sphera Funds Management LTD. (1.72%). Company insiders that own Genocea Biosciences stock include Eric S Hoffman, Jessica Baker Flechtner, Jonathan Poole and William D Clark. View Institutional Ownership Trends for Genocea Biosciences.

Genocea Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., AXA and Dimensional Fund Advisors LP. View Insider Buying and Selling for Genocea Biosciences.

Genocea Biosciences' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, Northpointe Capital LLC, Vanguard Group Inc., TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Teachers Advisors LLC and California State Teachers Retirement System. Company insiders that have bought Genocea Biosciences stock in the last two years include Eric S Hoffman, Jonathan Poole and William D Clark. View Insider Buying and Selling for Genocea Biosciences.

Shares of Genocea Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Genocea Biosciences stock can currently be purchased for approximately $4.04.